RESTASIS ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
53	Sjogren syndrome	1
162	Pemphigoid	1

53. Sjogren syndrome

Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02004067 (ClinicalTrials.gov)	January 2013	3/12/2013	Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease	Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease	Primary Sjogren Syndrome;Secondary Sjogren Syndrome;Aqueous Deficient Dry Eye Disease;Evaporative Dry Eye Disease	Drug: Restasis;Drug: Refresh Endura	Federal University of São Paulo	Allergan	Completed	18 Years	65 Years	All	100	Phase 4	Brazil

Clinical trials : 90 / Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-000480-41-IT (EUCTR)	27/05/2008	10/06/2008	Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eyedrop treatment on patients with ocular cicatricial pemphigoid. - ND	Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eyedrop treatment on patients with ocular cicatricial pemphigoid. - ND	Ocular cicatricial pemphigoid (OCP) MedDRA version: 9.1;Level: LLT;Classification code 10010746;Term: Conjunctivitis chronic	Trade Name: RESTASIS INN or Proposed INN: Cyclosporine	UNIVERSITA' CAMPUS BIOMEDICO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy